Quantum, Veeam Team Up to Boost Data Protection and Cyber Resilience
QMCO strengthens its Veeam Ready qualifications to combat cyber threats and data recovery challenges effectively.
Quantum Biopharma Provides Corporate Update
TORONTO, ON / ACCESSWIRE / September 27, 2024 / Quantum BioPharma Ltd. (formerly, FSD Pharma Inc.) (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, is pleased to announce the following corporate updates.
Quantum BioPharma to Present at Global Growth and Investment Conference Presented by ArcStone Securities and Investments and Kingswood US
TORONTO, ON / ACCESSWIRE / September 25, 2024 / Quantum BioPharma Ltd. (formerly, FSD Pharma Inc.) (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, is pleased to announce that Jason Sawyer, Head of Finance and Mergers and Acquisitions, will present at the ArcStone-Kingswood Growth Summit held on September 26, 2024, in Toronto, ON.
Spectral Capital Corp (FCCN) Welcomes Quantum Visionary Dr. Wolf Kohn to Its Quantum Bridge Advisory Board
Revolutionizing the Future of Quantum Computing and AI with Industry Luminary Dr. Wolf Kohn NEW YORK, NY / ACCESSWIRE / September 24, 2024 / Spectral Capital Corporation (OTCQB:FCCN), a trailblazer in Quantum-as-a-Service (QaaS) and decentralized cloud infrastructure, is thrilled to announce the appointment of Dr. Wolf Kohn, Ph.D., a globally recognized leader in quantum computing, artificial intelligence, and data optimization, to its Quantum Bridge Advisory Board.
Exclusive: First Quantum Minerals offers voluntary retirement to Cobre Panama workers, sources say
Canadian miner First Quantum Minerals has opened a voluntary retirement (VR) scheme to workers at the Cobre Panama mine, two sources familiar with the matter told Reuters, as the company waits for a government decision on re-opening the facility.
Quantum Biopharma Signs an Agreement With Ingenu CRO to Conduct a Clinical Study to Observe Disease Progression in Patients With Primary Progressive Multiple Sclerosis
TORONTO, ON / ACCESSWIRE / September 9, 2024 / Quantum BioPharma Ltd. (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announces that through its subsidiary, HUGE Biopharma Australia Pty Ltd.
Quantum Biopharma Receives Nasdaq Notification of Regaining Compliance with Nasdaq's Minimum Bid Price Requirement and Completes Debt Settlements
TORONTO, ON / ACCESSWIRE / September 6, 2024 / Quantum BioPharma Ltd. (formerly, FSD Pharma Inc.) (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, is pleased to announce that it has received a formal notice from The Nasdaq Stock Market, LLC ("Nasdaq") stating that the Company has regained compliance with the minimum bid price requirement set forth in Rule 5550(a)(2) of the Nasdaq Listing Rules.
Quantum Biopharma Announces Celly Nutrition Launches unbuzzd(TM) Grab-and-Go Stick Packs on Amazon.com so you can "own NOW and what's NEXT"
TORONTO, ON / ACCESSWIRE / August 30, 2024 / Quantum BioPharma Ltd. (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announces that highly-anticipated launch of unbuzzd™, a groundbreaking product designed to help individuals recover from the adverse effects of alcohol consumption and prepare for what's next.
Quantum Increases its Per Share Price With Reverse Stock Split
To raise its share price and ensure compliance with Nasdaq's listing requirements, QMCO implements a 1-for-20 reverse stock split.
Quantum Biopharma Announces Intention to Complete Debt Settlements and Provides Corporate Update
TORONTO, ON / ACCESSWIRE / August 23, 2024 / Quantum BioPharma Ltd. (formerly, FSD Pharma Inc.) (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, is pleased to announce the following corporate updates.
Quantum (QMCO) Q1 Loss Wider Than Expected, Sales Fall Y/Y
Quantum's (QMCO) Q1 fiscal 2025 performance is affected by weakness across Product, Service and subscription and Royalty business segments.
Quantum Corporation (QMCO) Q1 2025 Earnings Call Transcript
Quantum Corporation (NASDAQ:QMCO ) Q1 2025 Earnings Conference Call August 13, 2024 5:00 PM ET Company Participants Brian Cabrera – Chief Administrative Officer Jamie Lerner – Chairman and Chief Executive Officer Ken Gianella – Chief Financial Officer Conference Call Participants Neal Chokshi – Northland Capital Markets Max Michaelis – Lake Street Capital Markets Operator Greetings, welcome to Quantum Corporation's First Quarter Fiscal Year 2025 Financial Results. At this time all participants are in a listen-only mode.
